Natera, Inc. (NASDAQ:NTRA) Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 1.2% during the third quarter, Holdings Channel reports. The firm owned 143,903 shares of the medical research company’s stock after acquiring an additional 1,685 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Natera were worth $18,269,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Natera by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock worth $1,010,152,000 after purchasing an additional 72,848 shares during the period. O Shaughnessy Asset Management LLC acquired a new position in shares of Natera in the first quarter valued at approximately $220,000. Natixis acquired a new stake in shares of Natera during the first quarter worth $758,000. Magnetar Financial LLC grew its position in Natera by 52.5% in the 1st quarter. Magnetar Financial LLC now owns 176,643 shares of the medical research company’s stock valued at $16,156,000 after buying an additional 60,814 shares during the last quarter. Finally, Hood River Capital Management LLC acquired a new position in Natera in the 1st quarter valued at $2,821,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on NTRA shares. Piper Sandler lifted their target price on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday. Leerink Partners boosted their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. TD Cowen raised their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Canaccord Genuity Group upped their price objective on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, The Goldman Sachs Group upped their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $140.59.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at approximately $25,141,737.28. This represents a 2.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares of the company’s stock, valued at approximately $3,073,262.58. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,821 shares of company stock valued at $4,776,878. Company insiders own 7.60% of the company’s stock.

Natera Stock Up 3.6 %

Shares of NASDAQ:NTRA opened at $167.88 on Thursday. Natera, Inc. has a 12-month low of $53.62 and a 12-month high of $169.71. The stock’s 50-day moving average price is $129.84 and its two-hundred day moving average price is $117.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market cap of $22.16 billion, a price-to-earnings ratio of -95.39 and a beta of 1.53.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same quarter in the prior year, the business posted ($0.95) earnings per share. Natera’s revenue for the quarter was up 63.9% compared to the same quarter last year. On average, research analysts forecast that Natera, Inc. will post -1.7 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.